Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG ‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis ( IFE ) systems and reagents
Cancer Medicine · 2024
DOI: 10.1002/cam4.70128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yuko Shirouchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Multiple Myeloma, Antibodies, Monoclonal, Humanized, Myeloma Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immunofixation electrophoresis (IFE) is the standard method for confirming the presence of a monoclonal protein (M‐protein) at multiple myeloma (MM) diagnosis. IFE is also essential at assessment of complete response (CR) and stringent CR during treatment. As the CR assessment is influenced by daratumumab and isatuximab, HYDRASHIFT assays were developed.
Methods
Samples from patients under treatment that included daratumumab or isatuximab were tested and monitored by IFE on the HYDRASYS system using HYDRASHIFT assays (HYDRASYS/HYDRASHIFT) and by IFE on the Epalyzer2 system (Epalyzer).
Results
The IFE using HYDRASYS/HYDRASHIFT avoided a false positive caused by drug‐related IgG‐κ and contributed to accurate assessment of CR. Furthermore, HYDRASYS/HYDRASHIFT detected small M‐proteins at early relapse and detected free light chains (FLCs) in patients with renal impairment exhibiting high serum FLCs despite being often missed on Epalyzer.
Conclusion
Sensitivity and specificity of M‐protein detection vary greatly depending on the IFE system and reagents used.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Clinical Laboratory, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Scientific Affairs, Sebia, Japan.
- Application, Sebia, Japan.
ORCID-Profile: Yuko Shirouchi, Dai Maruyama
Zitieren
APA
Shirouchi, Y., Kaihara, K., Sekita, T., Amano, N., Nakayama, K., Miyake, K., Abe, H., Oinuma, H., & Maruyama, D. (2024). Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG ‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis ( IFE ) systems and reagents. Cancer Medicine. https://doi.org/10.1002/cam4.70128
Vancouver
Shirouchi Y, Kaihara K, Sekita T, Amano N, Nakayama K, Miyake K, et al. Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG ‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis ( IFE ) systems and reagents. Cancer Medicine. 2024. doi:10.1002/cam4.70128
BibTeX
@article{Shirouchi2024,
author = {Shirouchi, Yuko and Kaihara, Kazumi and Sekita, Tsunaki and Amano, Naoko and Nakayama, Konosuke and Miyake, Kazunori and Abe, Hitoshi and Oinuma, Hirotoshi and Maruyama, Dai},
title = {Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG ‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis ( IFE ) systems and reagents},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70128}
}
EUVIMED